Open AccessAll-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer – A phase II study
Author(s) -
Hanan Shawky,
Hesham Tawfik
Publication year - 2014
Publication title -
journal of egyptian national cancer institute/journal of the egyptian national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.398
H-Index - 22
eISSN - 2589-0409
pISSN - 1110-0362
DOI - 10.1016/j.jnci.2014.08.001
Subject(s) - medicine , capecitabine , lapatinib , rash , tolerability , mucositis , adverse effect , nausea , oncology , metastatic breast cancer , neutropenia , trastuzumab , breast cancer , gastroenterology , cancer , radiation therapy , toxicity , colorectal cancer
Approximately one-third of patients with advanced, HER2+ve breast cancer (BC) develop brain metastases (BMs). The aim of this study is to investigate efficacy and tolerability of the combination of lapatinib and capecitabine (LC) in HER2+ve BC patients with brain metastases (BCBM).